A case study of acenocoumarol sensitivity and genotype‐phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9
- 21 July 2006
- journal article
- case report
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (5) , 617-620
- https://doi.org/10.1111/j.1365-2125.2006.02688.x
Abstract
Aims: To determine the cause of a genotype‐phenotype discordancy for acenocoumarol sensitivity.Methods: A patient, highly sensitive to acenocoumarol, and previously determined to carry only a single CYP2C9 *3 allele, was genotyped for additional functionally defective alleles in the CYP2C9 and VKORC1 genes. Family members were also analyzed to trace the pedigree.Results: The acenocoumarol‐sensitive patient was found to possess, in addition to CYP2C9 *3 allele, a CYP2C9 *11 allele and the VKORC1 AA diplotype which were all traced back through the parental lines.Conclusions: Acenocoumarol sensitivity in this subject is the consequence of inheritance of multiple functionally defective alleles in both the CYP2C9 and VKORC1 genes. The study provides additional data in support of diminished CYP2C9 activity due to the presence of the rare *11 allele.Keywords
This publication has 20 references indexed in Scilit:
- In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dosePharmacogenetics and Genomics, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivityHuman Molecular Genetics, 2005
- Common VKORC1 and GGCX polymorphisms associated with warfarin doseThe Pharmacogenomics Journal, 2005
- Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivityBlood, 2005
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarinBlood, 2005
- Upstream and coding region CYP2C9 polymorphismsPharmacogenetics, 2004
- Discovery of new potentially defective alleles of human CYP2C9Pharmacogenetics, 2004
- Identification of a novel variant CYP2C9 allele in ChinesePharmacogenetics, 2004
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999